OPTIMIZE: 3 versus 12 months dual antiplatelet therapy after angioplasty with DES

Currently the recommendation is 12 months of dual antiplatelet after a drug-eluting stent angioplasty. This study compared the 3 – months versus 12 months of dual antiplatelet 

after angioplasty with zotarolimus-eluting stent in real-world patients. This was a prospective, multicenter study randomized 1563 patients to receive aspirin and clopidogrel for 3 months and 1556 to receive both drugs for 12 months. The primary end point was death, myocardial infarction, stroke and major bleeding at one year. No significant difference was observed between the two groups in the incidence of the primary end point with 5.8 % events for 12 months of dual anti platelet versus 6% for three months. With these results the strategy of three months reached the noninferiority criteria. There were no differences in the incidence of stent thrombosis.

1_fausto_feres
Fausto Feres
2013-10-31

Original title: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

More articles by this author

TRANSLATE-POPS: Routine measurement of platelet aggregation generates a minimal impact on the treatment setting

The high platelet reactivity is associated with adverse events after stent implantation. Current guidelines consider the measurement of aggregability as a class IIB and...

TATORT-NSTEMI: Routinely thromboaspiration in patients with non ST-elevation AMI

Thromboaspiration in patients with ST-elevation is being questioned while in patients without elevation this strategy has not been studied. The study included 440 patients...

REPRISE II: LOTUS valve for percutaneous aortic valve replacement

The aim of this study was to evaluate the safety and efficacy of the new device in patients with severe aortic stenosis at high...

GIANT: Evaluation of the genetic profile of CYP2C19 in patients undergoing primary angioplasty

The aim of this study was to evaluate the clinical impact resistance thienopyridines through genetic analysis of CYP2C19 receptor. The primary endpoint was  a...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...